Generic pharmaceutical company Apotex Corp Thursday awarded 25,000 fluvoxamine tablets and placebo tablets to the Duke Clinical Research Institute for the ACTIV-6 clinical study funded by the National Institutes of Health (NIH) to evaluate repurposed medications in the search for effective, safe treatments for mild-to-moderate COVID-19 for non-hospitalized patients.
ACTIV-6 is part of the NIH Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership to develop a coordinated research strategy for prioritizing and speeding up development of the most promising treatments and vaccines for COVID-19.
According to the company, fluvoxamine is among existing FDA-approved medications chosen for ACTIV-6 to further evaluate its effects on mild-to-moderate COVID-19.
In conjunction, NIH plans to establish whether the anti-inflammatory effects of fluvoxamine observed in nonclinical studies are seen in COVID-19 clinical studies. Many small-scale studies have shown positive therapeutic benefits of fluvoxamine, including a recent Canadian study that saw fluvoxamine curb the number of COVID-19 patients ending up in hospital by 30%.
Additionally, ACTIV-6 is a double-blind study expected to enrol nearly 15,000 participants. Potential participants are at least 30 years old, have tested positive for COVID-19 and are experiencing symptoms. The participation involves taking the medication and keeping track of symptoms over 90 days through online surveys, concluded the company.
NeoImmuneTech names new president and chief executive officer
BenevolentAI reports positive Phase Ia safety and pharmacokinetic data for BEN-8744
Thermo Fisher Scientific unveils CorEvitas registry for generalized pustular psoriasis
Nektar Therapeutics commences Phase 2b rezpegaldesleukin clinical trial for alopecia areata
Innovent Biologics doses first participant in first-in-human phase one clinical trial of IBI3002
Ananda Developments secures CBD Drug Supply Agreement for endometriosis clinical trial
Trellus Health secures agreement with major US health plan for IBD management
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins